Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Cyclophosphamide 50mg tablets
0801010H0AAAFAF
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | 18 |
|
Cyclophosphamide 100mg/5ml oral liquid
0801010H0AAARAR
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
|
Cyclophosphamide 1g powder for solution for injection vials
0801010H0AAADAD
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
|
Cyclophosphamide 200mg inj vials
0801010H0AAABAB
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
|
Cyclophosphamide 25mg tablets
0801010H0AAAKAK
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
|
Cyclophosphamide 25mg/5ml oral liquid
0801010H0AAAPAP
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
|
Cyclophosphamide 35mg/5ml oral liquid
0801010H0AAAMAM
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
|
Cyclophosphamide 40mg/5ml oral liquid
0801010H0AAAVAV
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
|
Cyclophosphamide 500mg inj vials
0801010H0AAACAC
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
|
Cyclophosphamide 50mg/5ml oral liquid
0801010H0AAANAN
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
|
Cyclophosphamide 75mg/5ml oral liquid
0801010H0AAAQAQ
|
Cyclophosphamide | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.